NMO Antibody-Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis
Arch Ophthalmol 126:566-570, Dinkin,M.J.,et al, 2008
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Decoding Cryptogenic Cardioembolism
Ann Neurol 64:364-365, Meschia,J.F., 2008
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
NMO-IgG in the Diagnosis of Neuromyelitis Optica
Neurol 68:1076-1077, Jarius,S.,et al, 2007
Revised Diagnostic Criteria for Neuromyelitis Optica
Neurol 66:1485-1489, Wingerchuk,D.M.,et al, 2006
Immune Reconstitution Inflammatory Syndrome in the CNS of HIV Infected Patients
Neurol 67:383-388, Venkataramana,A.,et al, 2006
Neuromyelitis Optica IgG Status in Acute Partial Transverse Myelitis
Arch Neurol 63:1398-1400, Scott,T.F.,et al, 2006
A Serum Autoantibody Marker of Neuromyelitis Optica: Distinction from Multiple Sclerosis
Lancet 364:2106-2112, Lennon,V.A.,et al, 2004
A Randomized Trial of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Neurol 54:603-607, Sanders,D.B.,et al, 2000
Familial Neuromyelitis Optica (Devics Syndrome) with Late Onset in Japan
Neurol 55:318-320, Yamakawa,K.,et al, 2000
Quantitative Assessment of Sustained-Release 4-Aminopyridine for Symptomatic Treatment of Multiple Sclerosis
Neurol 48:817-821, Schwid,S.R.,et al, 1997
A Gene for Parkinson Disease
Arch Neurol 54:1156-1157, Chase,T.N., 1997
Acute Ventilatory Failure in Lambert-Eaton Myasthenic Syndrome and Its Response to 3, 4-Diaminopyridine
Neurol 46:1143-1145, Smith,A.&Wald,J., 1996
Treatment with Oral 3, 4 Diaminopyridine Improves Leg Strength in Multiple Sclerosis Patients
Neurol 47:1457-1462, Bever,C.T.,et al, 1996
Lambert-Eaton Myasthenic Syndrome Presenting with Severe Respiratory Failure
Muscle & Nerve 19:1328-1333996., Nicolle,M.W.,et al, 1996
A Gene for Parkinson's Disease
BMJ 313:1278, Hawkes,C., 1996
4-Aminopyridine in the Treatment of Patients with Multiple Sclerosis:Long-term Efficacy and Safety
Arch Neurol 51:292-296, Polman,C.H.,et al, 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
The Effect of 4-Aminopyridine on Clinical Signs in Multiple Sclerosis
Ann Neurol 32:123-130, vanDiemen,H.A.M.,et al, 1992
4-Aminopyridine in Multiple Sclerosis:Prolonged Administration
Neurol 41:1344-1348, Stefoski,D.,et al, 1991
Preliminary Trial of 3, 4-Diaminopyridine in Patients with Multiple Sclerosis
Ann Neurol 27:421-427, Bever,C.T.,et al, 1990
Orally Administered 4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 27:186-192, Davis,F.A.,et al, 1990
3, 4-Diaminopyridine in the Treatment of Lambert-Eaton Myasthenic Syndrome
NEJM 321:1567-1571, 1607-16081989., McEvoy,K.M.,et al, 1989
4-Aminopyridine Improves Clinical Signs in Multiple Sclerosis
Ann Neurol 21:71-77, Stefoski,D.,et al, 1987
Clinical & Biochemical Correlates of Bradyphrenia in Parkinson's Disease
Neurol 37:1130-1134, Mayeux,R.,et al, 1987
The Clinical Syndrome of Striatal Dopamine Deficiency, Parkinsonism Induced by MPTP
NEJM 312:1418-1421, Burns,R.S.,et al, 1985
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
Memory Impairment in Korsakoff's Psychosis:A Correlation with Brain Noradrenergic Activity
Science 202:905-907, McEntee,W.J.,et al, 1978
4-Aminopyridine-A New Drug Tested in the Treatment of Eaton-Lambert Syndrome
JNNP 40:1109, Lundh,H.,et al, 1977